Windlas Biotech FY26 Revenue Up 19% to Rs 904 Cr

Windlas Biotech reported FY26 revenue of Rs 904 Cr, up 19% YoY, with Q4 revenue at Rs 238 Cr, up 18% YoY.
Adjusted EBITDA for FY26 stood at Rs 121 Cr (13.4% margin) and adjusted PAT at Rs 83 Cr (9.2% margin), excluding non-cash ESOP costs.
The company completed a Rs 47 Cr buyback and proposed a Rs 13 Cr dividend, maintaining a net debt-free position with Rs 251 Cr net liquidity.
Growth was driven by a 20% increase in Generic Formulations CDMO, 13% in Trade Generics, and 40% in Exports verticals.